Nanoviricides (NNVC)
Market Price (9/21/2026): $1.47 | Market Cap: $29.2 MilSector: Health Care | Industry: Biotechnology
Nanoviricides (NNVC)
Market Price (9/21/2026): $1.47Market Cap: $29.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Antiviral Therapies, Nanomedicine, Show more. | Weak multi-year price returns2Y Excs Rtn is -48%, 3Y Excs Rtn is -62% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.4 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -34% Key risksNNVC key risks include [1] uncertainty surrounding its clinical trial outcomes and regulatory approvals, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Antiviral Therapies, Nanomedicine, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -48%, 3Y Excs Rtn is -62% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.4 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -34% |
| Key risksNNVC key risks include [1] uncertainty surrounding its clinical trial outcomes and regulatory approvals, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Nanoviricides (NNVC) stock has lost about 20% since 5/31/2026 because of the following key factors:
1. Significant Dilutive Financing Activities: Nanoviricides engaged in multiple financing activities since May 31, 2026, which led to substantial dilution of its stock. On May 18, 2026, the company closed a registered direct offering raising approximately $2 million by selling 1,333,334 common shares (or pre-funded warrants) and accompanying warrants, with an exercise price of $1.75 per share. Subsequently, on July 27, 2026, the company announced another registered direct offering to generate approximately $3.8 million in gross proceeds through the sale of 2,516,339 common shares (or pre-funded warrants) and corresponding warrants. Furthermore, a shelf registration statement (S-3) filed on August 21, 2026, and a prospectus on September 2, 2026, detailed the potential to generate up to an additional $4.4 million through warrant exercises. These actions contributed to a significant increase in outstanding shares, with shareholders experiencing approximately 41.7% dilution over the past year.
2. Persistent Pre-Revenue Status and Continued Net Losses: As a clinical-stage biotechnology company, Nanoviricides remains pre-revenue, meaning it has no sales from commercialized products. For its fiscal Q3 2026, which ended on March 31, 2026 (the company's fiscal year ends on June 30), Nanoviricides reported a net loss of $(1.99) million. The ongoing absence of revenue, coupled with sustained operating expenses and net losses, has created investor apprehension regarding the company's financial sustainability and its long-term path to profitability.
Show more
Nanoviricides (NNVC) stock has lost about 20% since 5/31/2026 because of the following key factors:
1. Significant Dilutive Financing Activities: Nanoviricides engaged in multiple financing activities since May 31, 2026, which led to substantial dilution of its stock. On May 18, 2026, the company closed a registered direct offering raising approximately $2 million by selling 1,333,334 common shares (or pre-funded warrants) and accompanying warrants, with an exercise price of $1.75 per share. Subsequently, on July 27, 2026, the company announced another registered direct offering to generate approximately $3.8 million in gross proceeds through the sale of 2,516,339 common shares (or pre-funded warrants) and corresponding warrants. Furthermore, a shelf registration statement (S-3) filed on August 21, 2026, and a prospectus on September 2, 2026, detailed the potential to generate up to an additional $4.4 million through warrant exercises. These actions contributed to a significant increase in outstanding shares, with shareholders experiencing approximately 41.7% dilution over the past year.
2. Persistent Pre-Revenue Status and Continued Net Losses: As a clinical-stage biotechnology company, Nanoviricides remains pre-revenue, meaning it has no sales from commercialized products. For its fiscal Q3 2026, which ended on March 31, 2026 (the company's fiscal year ends on June 30), Nanoviricides reported a net loss of $(1.99) million. The ongoing absence of revenue, coupled with sustained operating expenses and net losses, has created investor apprehension regarding the company's financial sustainability and its long-term path to profitability.
3. Inherent Risks and Long Development Cycles of Clinical-Stage Biopharma: The biotechnology sector, especially for companies in the clinical stage like Nanoviricides, carries inherent risks related to the lengthy and uncertain nature of drug development. Despite positive news regarding its lead drug candidate NV-387, such as the regulatory approval for a Phase II clinical trial for Ebola in the Democratic Republic of Congo (announced on August 10, 2026) and the trial's scheduled start the week of September 15, 2026, the prolonged development timelines and the high probability of failure in clinical trials contribute to investor caution and volatility in the stock. Investors continuously weigh the potential future success against the significant scientific, regulatory, and financial uncertainties.
Show less
Stock Movement Drivers
Fundamental Drivers
The -20.2% change in NNVC stock from 5/31/2026 to 9/20/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312026 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.78 | 1.42 | -20.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 20 | 20 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| NNVC | -20.2% | |
| Market (SPY) | 0.9% | 31.6% |
| Sector (XLV) | 12.7% | -1.4% |
Fundamental Drivers
The 35.2% change in NNVC stock from 2/28/2026 to 9/20/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.05 | 1.42 | 35.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 20 | 20 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 9/20/2026| Return | Correlation | |
|---|---|---|
| NNVC | 35.2% | |
| Market (SPY) | 11.6% | 28.3% |
| Sector (XLV) | 5.5% | 13.9% |
Fundamental Drivers
The 2.2% change in NNVC stock from 8/31/2025 to 9/20/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312025 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.39 | 1.42 | 2.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 16 | 20 | -19.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 9/20/2026| Return | Correlation | |
|---|---|---|
| NNVC | 2.2% | |
| Market (SPY) | 19.4% | 27.8% |
| Sector (XLV) | 24.1% | 5.6% |
Fundamental Drivers
The -2.1% change in NNVC stock from 8/31/2023 to 9/20/2026 was primarily driven by a -41.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312023 | 9202026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.45 | 1.42 | -2.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 12 | 20 | -41.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2023 to 9/20/2026| Return | Correlation | |
|---|---|---|
| NNVC | -2.1% | |
| Market (SPY) | 75.6% | 15.9% |
| Sector (XLV) | 32.3% | 8.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NNVC Return | 30% | -70% | -8% | 40% | -21% | 24% | -51% |
| Peers Return | 51% | 0% | -9% | -17% | 2% | 112% | 146% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| NNVC Win Rate | 50% | 25% | 42% | 50% | 50% | 56% | |
| Peers Win Rate | 53% | 48% | 47% | 48% | 60% | 58% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| NNVC Max Drawdown | -53% | -72% | -40% | -63% | -46% | -45% | |
| Peers Max Drawdown | -35% | -35% | -36% | -43% | -40% | -24% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GILD, MRNA, REGN, VRTX, VIR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)
How Low Can It Go
| Event | NNVC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -27.7% | -18.8% |
| % Gain to Breakeven | 38.4% | 23.1% |
| Time to Breakeven | 8 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.9% | -9.5% |
| % Gain to Breakeven | 49.0% | 10.5% |
| Time to Breakeven | 162 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -24.0% | -6.7% |
| % Gain to Breakeven | 31.6% | 7.1% |
| Time to Breakeven | 40 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -24.1% | -33.7% |
| % Gain to Breakeven | 31.7% | 50.9% |
| Time to Breakeven | 27 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -37.9% | -19.2% |
| % Gain to Breakeven | 61.0% | 23.8% |
| Time to Breakeven | 35 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -20.3% | -12.2% |
| % Gain to Breakeven | 25.5% | 13.9% |
| Time to Breakeven | 23 days | 62 days |
In The Past
Nanoviricides's stock fell -27.7% during the 2025 US Tariff Shock. Such a loss loss requires a 38.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | NNVC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -27.7% | -18.8% |
| % Gain to Breakeven | 38.4% | 23.1% |
| Time to Breakeven | 8 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -32.9% | -9.5% |
| % Gain to Breakeven | 49.0% | 10.5% |
| Time to Breakeven | 162 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -24.0% | -6.7% |
| % Gain to Breakeven | 31.6% | 7.1% |
| Time to Breakeven | 40 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -24.1% | -33.7% |
| % Gain to Breakeven | 31.7% | 50.9% |
| Time to Breakeven | 27 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -37.9% | -19.2% |
| % Gain to Breakeven | 61.0% | 23.8% |
| Time to Breakeven | 35 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -20.3% | -12.2% |
| % Gain to Breakeven | 25.5% | 13.9% |
| Time to Breakeven | 23 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -34.1% | -17.9% |
| % Gain to Breakeven | 51.9% | 21.8% |
| Time to Breakeven | 665 days | 123 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -53.0% | -8.6% |
| % Gain to Breakeven | 112.8% | 9.5% |
| Time to Breakeven | 251 days | 47 days |
In The Past
Nanoviricides's stock fell -27.7% during the 2025 US Tariff Shock. Such a loss loss requires a 38.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Nanoviricides (NNVC)
NanoViricides, Inc. (NNVC) is a nano-biopharmaceutical research and development company dedicated to discovering, developing, and ultimately commercializing drugs for the treatment of various viral infections. The company utilizes a proprietary nanoviricide technology platform to create novel antiviral therapies. Its core business revolves around advancing drug candidates through the research and development pipeline with the aim of bringing effective treatments to market for a range of viral diseases.
The company's main products are its drug candidates currently under development, each targeting specific viral pathogens. Key programs include the Human Coronavirus Program, focused on developing treatments for COVID-19 and seasonal coronaviruses, and the comprehensive HerpeCide program. The HerpeCide platform encompasses dermal topical and eye drop formulations for conditions like shingles, chickenpox, herpes, and ocular herpes keratitis, as well as an intraocular injection for viral acute retinal necrosis. Other significant drug candidates include FluCide, a broad-spectrum anti-influenza nanoviricide available in injectable and oral forms, DengueCide for various types of Dengue viruses, and HIVCide, an escape-resistant anti-HIV nanoviricide.
NanoViricides also maintains a broader pipeline, pursuing other nanoviricides drug projects for different viruses and indications, along with expansions within its HerpeCide program for additional herpes viruses. The primary customers and markets it aims to serve are patients suffering from a wide array of viral infections globally. These include individuals afflicted by common conditions like influenza and herpes, as well as those with more severe or chronic viral diseases such as COVID-19, dengue, and HIV, addressing significant unmet medical needs in antiviral therapeutics.
AI Analysis | Feedback
A Moderna, but focused on developing antiviral treatments using nanotechnology.
An early-stage Gilead Sciences, but for a broad range of viral infections using nanotechnology.
AI Analysis | Feedback
- Human Coronavirus Program: Develops drugs for COVID-19 and seasonal coronavirus infections.
- HerpeCide Dermal Topical and Eye Drops: Treats various herpes-related conditions including shingles, chickenpox, and ocular herpes keratitis.
- HerpeCide IntraOcular Injection: Designed for the treatment of viral acute retinal necrosis.
- FluCide Broad-Spectrum Anti-Influenza nanoviricide: An anti-influenza drug available as an injectable for hospitalized patients and an oral formulation for outpatients.
- DengueCide: A nanoviricide drug project aimed at treating various types of Dengue viruses.
- HIVCide: An escape-resistant anti-HIV nanoviricide under development.
AI Analysis | Feedback
Based on the provided company description, Nanoviricides, Inc. (NNVC) is primarily a nano-biopharmaceutical research and development company focused on discovering, developing, and commercializing drugs for the treatment of viral infections. The description details various drug candidates the company is developing (e.g., for COVID-19, herpes, influenza, dengue, HIV).
As an R&D company in the drug development phase, it typically does not yet have approved products on the market generating significant sales, nor does it have major customers in the traditional sense who purchase its finished drug products. The term "commercializes" likely refers to the future intent once drugs are approved. Therefore, based on the information provided, Nanoviricides (NNVC) does not currently have major customers for its drug products.
AI Analysis | Feedback
AI Analysis | Feedback
Dr. Irach B. Taraporewala, Chief Executive Officer
Dr. Irach B. Taraporewala was appointed Chief Executive Officer of NanoViricides, Inc. in July 2018. He is a seasoned pharmaceutical executive with over 25 years of experience in drug development and regulatory strategy. Prior to joining NanoViricides, he served as the founding CEO and President of Ohr Pharmaceutical, Inc. from April 2010 to December 2015, where he guided the company from preclinical stages through successful Phase II clinical trials. He also founded and managed Sitara Pharmaceutical Consulting, LLC. Dr. Taraporewala possesses a strong scientific background combined with significant management, leadership, business development, and financing expertise.
Meeta Vyas, Chief Financial Officer
Meeta Vyas serves as the Chief Financial Officer of NanoViricides, Inc. She was notably the first Indian woman to be named CEO of a publicly listed US corporation.
Dr. Anil R. Diwan, President & Executive Chairman
Dr. Anil R. Diwan co-founded NanoViricides, Inc. in 2005 and has been its President and Chairman of the Board since its inception. He is a prolific inventor and serial entrepreneur who invented novel polymeric micelle-based nanomedicine technologies. Before co-founding NanoViricides, Inc., he established TheraCour Pharma, Inc., a privately held company focused on nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., which held diverse portfolios including nanomedicines and device technologies. Dr. Diwan spearheaded the company's uplisting from the OTC Markets to NYSE-American in 2013 and has led several financing efforts since 2010. In 2014, he was recognized as "Researcher of the Year" by BusinessNewHaven.
Dr. Randall Barton, Chief Scientific Officer (Consulting)
Dr. Randall Barton serves as the Chief Scientific Officer (Consulting) for NanoViricides, Inc. He brings over 25 years of experience in drug discovery and development. Previously, he was the Director of In-Vivo Cardiovascular Research at Boehringer-Ingelheim. Dr. Barton is an expert in receptor-based drug design and has authored over 80 scientific publications and holds 5 patents. He also served on the faculty at the University of Connecticut Medical School.
Jayant Tatake, Vice President of R&D
Jayant Tatake is the Vice President of R&D at NanoViricides, Inc. He is a co-inventor of the company's nanomedicine technologies. Mr. Tatake has over 30 years of experience in the production of pharmaceuticals, ranging from lab scale to cGMP manufacture, and over 25 years of experience in Organic Chemistry, Research, and Process Development.
AI Analysis | Feedback
The key risks to NanoViricides' business, listed in order of significance, are:
-
Clinical Trial and Regulatory Approval Risk
As a nano-biopharmaceutical research and development company, NanoViricides' core business success is contingent upon the successful completion of clinical trials and obtaining regulatory approvals for its drug candidates. The company's lead candidate, NV-387, is currently advancing into Phase II human clinical trials for Mpox and is also being developed for various respiratory viral infections. Failure at any stage of clinical development, or an inability to secure necessary regulatory approvals (such as from the FDA), would significantly impede the company's ability to commercialize its drugs and generate revenue.
-
Funding and Liquidity Risk
NanoViricides is a clinical-stage company with limited revenue, making it heavily reliant on external financing to fund its extensive research and development activities. The drug development process is lengthy and capital-intensive, requiring substantial ongoing investment. While the company has recently undertaken financing events and management states current funding is sufficient for the planned Phase II Mpox trial, there is an inherent risk of needing additional capital in the future. Such needs could lead to further shareholder dilution through equity offerings.
-
Competition and Market Adoption Risk
The pharmaceutical industry, particularly in the antiviral space, is highly competitive. NanoViricides faces competition from both larger pharmaceutical companies and other biotechnology firms developing treatments for similar viral infections. Even if NanoViricides successfully develops and obtains regulatory approval for its drug candidates, there is no guarantee of widespread market adoption. Factors such as the efficacy, safety, cost, and marketing of competing products could impact the commercial success of NanoViricides' drugs.
AI Analysis | Feedback
AI Analysis | Feedback
The addressable markets for Nanoviricides' main products and services are estimated as follows:
- Human Coronavirus Program for COVID-19 seasonal coronavirus affliction: The global COVID-19 therapeutics market size was valued at US$ 30.7 billion in 2021 and is projected to reach more than US$ 16.2 billion by the end of 2031.
-
HerpeCide Dermal Topical and Eye Drops (for herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis):
- For general Herpes Simplex Virus (HSV) treatment, the global market size was valued at USD 2.7 billion in 2024 and is estimated to reach USD 4.0 billion by 2033.
- Specifically for genital herpes treatment, the global market size was valued at USD 2.63 billion in 2024 and is projected to reach USD 3.73 billion by 2033.
- For ocular herpes (herpes simplex keratitis) treatment, the global market is projected to grow from USD 5.0 billion in 2025 to USD 8.6 billion by 2035.
-
HerpeCide Dermal Topical and Eye Drops (for shingles, PHN, chickenpox):
- The global herpes zoster (shingles) treatment market was valued at USD 248.92 million in 2024 and is expected to reach USD 374.99 million by 2030.
- FluCide Broad-Spectrum Anti-Influenza nanoviricide: The global influenza treatment market size was estimated at USD 5.91 billion in 2023 and is projected to reach USD 6.44 billion by 2030.
- DengueCide for treatment of various types of Dengue viruses: The global dengue fever treatment market is projected to reach USD 1.26 billion in 2025 and is expected to grow to USD 7.44 billion by 2035.
- HIVCide, an escape-resistant anti-HIV nanoviricide: The global human immunodeficiency virus therapeutics market was valued at USD 39 billion in 2024 and is projected to grow to USD 54.8 billion by 2034.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Nanoviricides (NNVC) over the next 2-3 years:
- Advancement and Commercialization of NV-387 for Mpox (Monkeypox): Nanoviricides has completed manufacturing of NV-387 Oral Gummies, its Phase II clinical drug product, and has secured regulatory clearance to commence a Phase II trial for Mpox in the Democratic Republic of Congo. Additionally, the company filed for Orphan Drug Designation with the US FDA for NV-387 as a treatment for Mpox in February 2026, which, if granted and approved, could offer incentives such as seven years of market exclusivity.
- Advancement and Commercialization of NV-387 for Broad-Spectrum Respiratory Viral Infections: The company is developing NV-387 as a broad-spectrum antiviral to target various respiratory viral infections, including influenza, RSV, and coronaviruses. Nanoviricides projects that this indication alone could address a market exceeding $20 billion upon approval, and it is planning a Phase II trial for the empiric treatment of these infections.
- Strategic Pipeline Development for Broad Applications: Nanoviricides' strategy revolves around developing drugs like NV-387 that have broad applications across multiple indications. This approach aims to streamline regulatory development, minimize costs, and achieve faster timelines to commercialization. The company anticipates that this broad applicability will establish a robust commercial foundation and significantly improve returns once NV-387 reaches the commercial stage and begins generating revenue.
AI Analysis | Feedback
Share Issuance
- The number of shares outstanding for NanoViricides, Inc. increased by 32.23% in one year.
Capital Expenditures
- Capital expenditures for NanoViricides were approximately $94,516 in the last 12 months.
- Projected capital expenditures were $324,300 in 2021, $151,700 in 2022, $156,600 in 2023, $57,000 in 2024, $51,300 in 2025, and are projected to be $48,700 in 2026.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 16.2% | 43.2% | 90.1% | CAH 392% · MCK 346% · COR 168% |
| Managed Health Care | 8 | 40.4% | -5.3% | 2.3% | OSCR 84% · HQY 56% · ELV 17% |
| Health Care Services | 20 | 21.1% | 37.6% | -0.3% | HIMS 239% · RDNT 173% · DGX 76% |
| Health Care Facilities | 24 | 6.0% | 6.5% | -4.5% | NHC 271% · THC 261% · ENSG 129% |
| Health Care Equipment | 50 | -2.7% | -0.2% | -21.1% | POCI 11050% · UFPT 341% · GKOS 222% |
| Pharmaceuticals | 62 | -10.5% | 14.8% | -38.6% | LQDA 2472% · INDV 1099% · ETON 1051% |
| Health Care Supplies | 12 | 14.1% | -8.9% | -39.7% | LNTH 287% · HAE 54% · MMSI 20% |
| Life Sciences Tools & Services | 109 | 4.3% | -11.3% | -68.4% | SNWV 1757% · MEDP 231% · NTRA 199% |
| Health Care Technology | 21 | -25.8% | -52.6% | -79.2% | SPOK 68% · HSTM 3% · VEEV -13% |
| Biotechnology ← | 364 | 0.6% | -21.7% | -79.4% | CELZ 1280% · DNTH 1221% · ELVN 1069% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 152.07 |
| Mkt Cap | 71.0 |
| Rev LTM | 7,399 |
| Op Inc LTM | 2,083 |
| FCF LTM | 1,784 |
| FCF 3Y Avg | 975 |
| CFO LTM | 2,143 |
| CFO 3Y Avg | 1,196 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.3% |
| Rev Chg 3Y Avg | 7.0% |
| Rev Chg Q | 12.5% |
| QoQ Delta Rev Chg LTM | 3.0% |
| Op Inc Chg LTM | 9.7% |
| Op Inc Chg 3Y Avg | -4.9% |
| Op Mgn LTM | 26.9% |
| Op Mgn 3Y Avg | 23.9% |
| QoQ Delta Op Mgn LTM | 1.1% |
| CFO/Rev LTM | 30.1% |
| CFO/Rev 3Y Avg | 19.6% |
| FCF/Rev LTM | 23.0% |
| FCF/Rev 3Y Avg | 15.7% |
Price Behavior
| Market Price | $1.42 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/26/2005 | |
| Distance from 52W High | -30.0% | |
| 50 Days | 200 Days | |
| DMA Price | $1.38 | $1.26 |
| DMA Trend | down | down |
| Distance from DMA | 2.6% | 12.5% |
| 3M | 1YR | |
| Volatility | 73.0% | 89.6% |
| Downside Capture | 110.91 | 213.06 |
| Upside Capture | 106.83 | 173.48 |
| Correlation (SPY) | 17.7% | 28.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.22 | 0.63 | 1.76 | 1.84 | 1.89 | 0.91 |
| Up Beta | -0.40 | -0.16 | 2.99 | 2.47 | 1.05 | 0.64 |
| Down Beta | -0.73 | -0.94 | 1.43 | 2.06 | 2.79 | 1.19 |
| Up Capture | 46% | 88% | 49% | 172% | 205% | 51% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 7 | 17 | 25 | 55 | 104 | 320 |
| Down Capture | 552% | 182% | 206% | 138% | 155% | 101% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 13 | 23 | 37 | 68 | 136 | 379 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NNVC | |
|---|---|---|---|---|
| NNVC | -1.4% | 89.2% | 0.36 | - |
| Sector ETF (XLV) | 24.4% | 16.1% | 1.16 | 5.6% |
| Equity (SPY) | 16.9% | 12.9% | 0.94 | 28.7% |
| Gold (GLD) | 19.1% | 29.3% | 0.60 | 6.8% |
| Commodities (DBC) | 46.3% | 20.6% | 1.73 | -2.7% |
| Real Estate (VNQ) | 4.9% | 13.6% | 0.10 | -2.7% |
| Bitcoin (BTCUSD) | -30.6% | 44.3% | -0.70 | 20.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NNVC | |
|---|---|---|---|---|
| NNVC | -18.4% | 96.9% | 0.21 | - |
| Sector ETF (XLV) | 6.4% | 15.2% | 0.24 | 10.9% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 16.5% |
| Gold (GLD) | 19.1% | 18.8% | 0.83 | 7.5% |
| Commodities (DBC) | 11.2% | 19.5% | 0.45 | 1.1% |
| Real Estate (VNQ) | 1.1% | 18.8% | -0.05 | 8.7% |
| Bitcoin (BTCUSD) | 12.5% | 52.5% | 0.42 | 7.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NNVC | |
|---|---|---|---|---|
| NNVC | -26.9% | 119.5% | 0.24 | - |
| Sector ETF (XLV) | 10.6% | 16.7% | 0.51 | 1.9% |
| Equity (SPY) | 15.1% | 18.0% | 0.72 | 4.0% |
| Gold (GLD) | 12.1% | 16.4% | 0.61 | 6.8% |
| Commodities (DBC) | 8.3% | 18.1% | 0.37 | -2.0% |
| Real Estate (VNQ) | 4.4% | 20.7% | 0.18 | 2.4% |
| Bitcoin (BTCUSD) | 62.6% | 66.2% | 1.02 | 4.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 09/29/2025 | 10-K |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 09/27/2024 | 10-K |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 02/14/2024 | 10-Q |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 10/13/2023 | 10-K |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 10/13/2022 | 10-K |
| 03/31/2022 | 05/16/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 09/29/2025 | 10-K |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 09/27/2024 | 10-K |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 02/14/2024 | 10-Q |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 10/13/2023 | 10-K |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/14/2023 | 10-Q |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 10/13/2022 | 10-K |
| 03/31/2022 | 05/16/2022 | 10-Q |
| 12/31/2021 | 02/14/2022 | 10-Q |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 10/12/2021 | 10-K |
| 03/31/2021 | 05/14/2021 | 10-Q |
| 12/31/2020 | 02/16/2021 | 10-Q |
| 09/30/2020 | 11/16/2020 | 10-Q |
| 06/30/2020 | 10/13/2020 | 10-K |
| 03/31/2020 | 06/22/2020 | 10-Q |
| 12/31/2019 | 02/14/2020 | 10-Q |
| 09/30/2019 | 11/15/2019 | 10-Q |
| 06/30/2019 | 08/23/2019 | 10-K |
| 03/31/2019 | 05/15/2019 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.